NCCN Hematologic Malignancies Congress | Conference

Erin Kopp on the Toxicities of Cutaneous T-cell Lymphoma Treatment

October 6th 2016

Erin Kopp, ACNP-BC, City of Hope Comprehensive Cancer Center, on managing the side effects of cutaneous T-cell lymphoma treatment.

Dr. Richard M. Stone on the Genetic Landscape in AML

October 6th 2016

Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).

Dr. Horwitz on Combination CHOP Regimens in Peripheral T-cell Lymphoma

October 5th 2016

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.

Dr. George Somlo on Advances in Multiple Myeloma

October 4th 2016

Dr. George Somlo, MD, medical oncologist, City of Hope, discusses recent highlights in multiple myeloma.

Dr. William Wierda on Role for Ibrutinib in Frontline CLL

October 3rd 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discuses which chronic lymphocytic leukemia patients may benefit from ibrutinib frontline therapy and questions that remain after the RESONATE-2 trial.

Approved Myeloma Agents Rapidly Incorporated Into NCCN Guidelines

October 2nd 2016

There have been 10 agents approved over the last 12 years for the treatment of patients with multiple myeloma, and pivotal data for each agent has supported rapid inclusion into the NCCN treatment algorithms.

Triplet Therapy, ASCT Frontline Standard for Multiple Myeloma

October 2nd 2016

The preferred primary therapy for patients with multiple myeloma is induction therapy with a triplet regimen followed by autologous stem cell transplantation, consolidation, and maintenance.

Ibrutinib or FCR: Wierda Discusses First-Line Options for CLL

October 2nd 2016

There has been some debate over what should be the standard frontline treatment for patients with chronic lymphocytic leukemia: ibrutinib or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.

Dr. Thomas LeBlanc on Patient Shared Decision-Making in Hematologic Malignancies

October 2nd 2016

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

Dr. Steven Coutre on Frontline Treatment Decisions in CLL

October 2nd 2016

Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).

Novel Agents Hold Significant Promise in Treatment of AML

October 1st 2016

Jessica K. Altman, MD, discussed the potential of agents poised to transform the landscape of acute myeloid leukemia.

Mesa Maps Out Present and Future of Myelofibrosis Care

October 1st 2016

Ruben Mesa, MD, discussed the latest NCCN treatment guidelines for myelofibrosis and emerging treatments in the field.

Incorporating Generic Imatinib Into Frontline Treatment for CML

October 1st 2016

As generic imatinib enters the market, new questions focus on a renewed role for the agent in conjunction with second-generation TKIs.

Dr. Jerald Radich on Impact of Generic Imatinib in CML

October 1st 2016

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the impact of the approval of generic imatinib in chronic myelogenous leukemia (CML).

Dr. Ruben Mesa on New NCCN Guidelines for MPNs

October 1st 2016

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN). Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).